195 related articles for article (PubMed ID: 31725008)
1. Intestinal dialysis for conservative management of Uremia.
Puri I; Shirazi NM; Yap E; Saggi SJ
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):64-70. PubMed ID: 31725008
[TBL] [Abstract][Full Text] [Related]
2. Novel conservative management of chronic kidney disease via dialysis-free interventions.
Zarantonello D; Rhee CM; Kalantar-Zadeh K; Brunori G
Curr Opin Nephrol Hypertens; 2021 Jan; 30(1):97-107. PubMed ID: 33186220
[TBL] [Abstract][Full Text] [Related]
3. Conservative vs. preservative management of chronic kidney disease: similarities and distinctions.
Rhee CM; Nguyen DV; Nyamathi A; Kalantar-Zadeh K
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):92-102. PubMed ID: 31743240
[TBL] [Abstract][Full Text] [Related]
4. Challenges of reducing protein-bound uremic toxin levels in chronic kidney disease and end stage renal disease.
Faria M; de Pinho MN
Transl Res; 2021 Mar; 229():115-134. PubMed ID: 32891787
[TBL] [Abstract][Full Text] [Related]
5. Novel intestinal dialysis interventions and microbiome modulation to control uremia.
Sumida K; Lau WL; Kalantar-Zadeh K; Kovesdy CP
Curr Opin Nephrol Hypertens; 2022 Jan; 31(1):82-91. PubMed ID: 34846313
[TBL] [Abstract][Full Text] [Related]
6. Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease.
Kalantar-Zadeh K; Joshi S; Schlueter R; Cooke J; Brown-Tortorici A; Donnelly M; Schulman S; Lau WL; Rhee CM; Streja E; Tantisattamo E; Ferrey AJ; Hanna R; Chen JLT; Malik S; Nguyen DV; Crowley ST; Kovesdy CP
Nutrients; 2020 Jun; 12(7):. PubMed ID: 32610641
[TBL] [Abstract][Full Text] [Related]
7. [Renal replacement therapy by hemodialysis: an overview].
Jacobs C
Nephrol Ther; 2009 Jul; 5(4):306-12. PubMed ID: 19481513
[TBL] [Abstract][Full Text] [Related]
8. Commentary on the NICE guideline on renal replacement therapy and conservative management.
Kharbanda K; Iyasere O; Caskey F; Marlais M; Mitra S
BMC Nephrol; 2021 Aug; 22(1):282. PubMed ID: 34416872
[TBL] [Abstract][Full Text] [Related]
9. Comparison of survival analysis and palliative care involvement in patients aged over 70 years choosing conservative management or renal replacement therapy in advanced chronic kidney disease.
Hussain JA; Mooney A; Russon L
Palliat Med; 2013 Oct; 27(9):829-39. PubMed ID: 23652841
[TBL] [Abstract][Full Text] [Related]
10. [Clinical issues with uremia].
Girndt M
Internist (Berl); 2012 Jul; 53(7):817-22. PubMed ID: 22684210
[TBL] [Abstract][Full Text] [Related]
11. Disposition and clinical implications of protein-bound uremic toxins.
Jansen J; Jankowski J; Gajjala PR; Wetzels JFM; Masereeuw R
Clin Sci (Lond); 2017 Jul; 131(14):1631-1647. PubMed ID: 28667064
[TBL] [Abstract][Full Text] [Related]
12. Seeking an optimal renal replacement therapy for the chronic kidney disease epidemic: the case for on-line hemodiafiltration.
Gatti E; Ronco C
Contrib Nephrol; 2011; 175():170-185. PubMed ID: 22188699
[TBL] [Abstract][Full Text] [Related]
13. Design of a new therapy for patients with chronic kidney disease: use of microarrays for selective hemoadsorption of uremic wastes and toxins to improve homeostasis.
Shahidi Bonjar MR; Shahidi Bonjar L
Drug Des Devel Ther; 2015; 9():625-9. PubMed ID: 25653500
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. Renal versus continuous versus intermittent therapies for removal of uremic toxins.
Clark WR; Henderson LW
Kidney Int Suppl; 2001 Feb; 78():S298-303. PubMed ID: 11169030
[TBL] [Abstract][Full Text] [Related]
16. Uremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics.
Vitetta L; Gobe G
Mol Nutr Food Res; 2013 May; 57(5):824-32. PubMed ID: 23450842
[TBL] [Abstract][Full Text] [Related]
17. Decision-making for people with dementia and advanced kidney disease: a secondary qualitative analysis of interviews from the Conservative Kidney Management Assessment of Practice Patterns Study.
Scott J; Owen-Smith A; Tonkin-Crine S; Rayner H; Roderick P; Okamoto I; Leydon G; Caskey F; Methven S
BMJ Open; 2018 Nov; 8(11):e022385. PubMed ID: 30420346
[TBL] [Abstract][Full Text] [Related]
18. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies.
Hamed SA
Expert Rev Clin Pharmacol; 2019 Jan; 12(1):61-90. PubMed ID: 30501441
[No Abstract] [Full Text] [Related]
19. Future Avenues to Decrease Uremic Toxin Concentration.
Vanholder RC; Eloot S; Glorieux GL
Am J Kidney Dis; 2016 Apr; 67(4):664-76. PubMed ID: 26500179
[TBL] [Abstract][Full Text] [Related]
20. Keto-analogues and essential aminoacids and other supplements in the conservative management of chronic kidney disease.
Cupisti A; Bolasco P
Panminerva Med; 2017 Jun; 59(2):149-156. PubMed ID: 28001026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
